The Modern Regulatory Era: AI, Regulatory Intelligence, Global Harmonization, and Risk-Based Transformation in Pharmaceutical Development
DOI:
https://doi.org/10.47392/Eclearnix.2026.B070Abstract
The Modern Regulatory Era: AI, Regulatory Intelligence, Global Harmonization, and Risk-Based Transformation in Pharmaceutical Development
Table of Contents
CHAPTER 1 Introduction
CHAPTER 2 Foundations of Pharmaceutical Law and Governance
CHAPTER 3 The Architecture of Global Harmonization
CHAPTER 4 Principles of Risk-Based Regulation
CHAPTER 5 Regulatory Intelligence Frameworks
CHAPTER 6 Data Standards and Electronic Submissions
CHAPTER 7 Preclinical Development and Translational Pathways
CHAPTER 8 Clinical Trial Design and Adaptive Protocols
CHAPTER 9 Chemistry, Manufacturing, and Controls and Quality by Design
CHAPTER 10 Expedited and Accelerated Approval Mechanisms
CHAPTER 11 Artificial Intelligence in Drug Discovery and Design
CHAPTER 12 Artificial Intelligence in Clinical Trials and Operations
CHAPTER 13 Real-World Data and Real-World Evidence
CHAPTER 14 Automated Regulatory Intelligence and Dossier Generation
CHAPTER 15 Biosimilars, Biologics, and Advanced Therapies
CHAPTER 16 Digital Health, Medical Software, and Convergence
CHAPTER 17 Pharmacovigilance and Post-Market Lifecycle Management
CHAPTER 18 Global Health Authority Inspections and Compliance Audits
CHAPTER 19 Comparative Regulatory Case Studies
CHAPTER 20 Strategic Horizons and Concluding Synthesis
Downloads
Published
Issue
Section
License
Copyright (c) 2026 International Research Journal on Advanced Engineering and Management (IRJAEM)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
.